EHF (n = 8) | Non-EHF (n = 28) | p-value | |
---|---|---|---|
Age yrs (median, IQR) | 37 (33-42) | 33 (28-40) | 0.25 |
Male gender | 88% | 43% | 0.12 |
HBeAg positive | 50% | 64% | 0.47 |
Alcohol (> 3units/day) | 25% | 25% | 1.00 |
Cirrhosis | 20% | 42% | 0.36 |
HBV Genotype C | 75% | 82% | 0.28 |
BMI kg/m2 (median. IQR) | 19 (18-20) | 20 (18-22) | 0.20 |
BL CD4 cells/mm3 (median. IQR) | 52 (18-131) | 32 (19-214) | 0.96 |
BL HIV RNA log10 c/ml (median. IQR) | 4.9 (4.7-5.1) | 4.7 (4.3-5.1) | 0.22 |
BL ALT IU/L (median. IQR) | 79 (59-96) | 36 (22-59) | 0.008* |
BL HBV DNA log10 c/ml (median. IQR) | 9.9 (8.4-10.4) | 8.4 (7.8-9.0) | 0.009* |
Randomised HBV therapy | 3TC n = 5 | 3TC n = 8 | 0.193 |
TDF n = 2 | TDF n = 10 | ||
3TC/TDF n = 1 | 3TC/TDF n = 10 | ||
OI prophylaxis (fluconazole and/or cotrimoxazole) | 88% | 61% | 0.162 |
Izoniazid therapy | 0% | 21% | 0.302 |